Affinium doses first patient in AFN-1252 drug trial
AFN-1252, the clinical candidate from the company’s FASII program, is designed to selectively target the staphylococcal FabI enzyme. The Phase 2 trial is designed to confirm efficacy and
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.